{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:30:59Z","timestamp":1795210259990,"version":"4.10.3"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009043","name":"University of Patras","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009043","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Excessive body weight stands out as a major, well-documented risk factor for rheumatic and musculoskeletal diseases (RMDs). Indeed, high body mass index (BMI) affects disease severity, treatment response, and long-term outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were first developed for type 2 diabetes and obesity, but there is growing evidence that they may also have anti-inflammatory and immunomodulatory properties [1\u20133]. This narrative review examines the available evidence on the role of GLP-1 RAs in two conditions that are strongly associated with metabolic and mechanical factors but sit on almost opposite ends of the inflammatory spectrum: osteoarthritis (OA), a predominantly mechanically driven disease, and psoriatic disease (PsD), an immune-mediated inflammatory disease. A comprehensive narrative review of the literature was conducted to evaluate preclinical and clinical evidence regarding the effects of GLP-1 signaling in both OA and PsD. Preclinical data suggest that GLP-1 signaling may protect cartilage, reduce inflammation, and alleviate pain in OA. Early clinical evidence is encouraging, showing reductions in both joint pain and body weight. In PsD, obesity and psoriatic inflammation share several common pathways, particularly through the IL-17\/IL-23 axis, which provides a theoretical biological rationale for GLP-1 RAs use in this setting, although direct clinical evidence remains limited and largely derived from studies in obese patients. Dedicated randomized controlled trials are necessary to clarify the direct immunomodulatory mechanisms involved and to define the precise position of GLP-1 RAs in rheumatological practice.<\/jats:p>","DOI":"10.1007\/s00296-026-06258-2","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:24:14Z","timestamp":1784690654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["GLP-1 receptor agonists in osteoarthritis and psoriatic disease: the missing link between obesity and inflammation?"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2589-2597","authenticated-orcid":false,"given":"Andreas","family":"Angelopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":false,"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6207-496X","authenticated-orcid":false,"given":"Charalampos","family":"Papagoras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-3655","authenticated-orcid":false,"given":"Dimitrios","family":"Daoussis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"6258_CR1","doi-asserted-by":"publisher","unstructured":"Karacabeyli D, Lacaille D (2025) Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions. Nat Rev Rheumatol Nat Res 671\u2013683. https:\/\/doi.org\/10.1038\/s41584-025-01302-0","DOI":"10.1038\/s41584-025-01302-0"},{"issue":"10431","key":"6258_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736","volume":"403","author":"NH Phelps","year":"2024","unstructured":"Phelps NH, Singleton RK, Zhou B, Heap RA, Mishra A, Bennett JE et al (2024) Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403(10431):1027\u20131050. https:\/\/doi.org\/10.1016\/S0140-6736(23)02750-2","journal-title":"Lancet"},{"issue":"1","key":"6258_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3122\/JABFM","volume":"25","author":"EM Matheson","year":"2012","unstructured":"Matheson EM, King DE, Everett CJ (2012) Healthy lifestyle habits and mortality in overweight and obese individuals. J Am Board Fam Med 25(1):9\u201315. https:\/\/doi.org\/10.3122\/JABFM2012.01.110164","journal-title":"J Am Board Fam Med"},{"issue":"4","key":"6258_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S2213-8587(22)00033-X","volume":"10","author":"M Kivim\u00e4ki","year":"2022","unstructured":"Kivim\u00e4ki M, Strandberg T, Pentti J, Nyberg ST, Frank P, Jokela M et al (2022) Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet Diabetes Endocrinol 10(4):253\u2013263. https:\/\/doi.org\/10.1016\/S0140-6736(23)02750-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6258_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103864","author":"E Bilgin","year":"2025","unstructured":"Bilgin E, Venerito V, Bogdanos DP (2025) Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: a review of current evidence and future directions. Autoimmun Reviews Elsevier B V. https:\/\/doi.org\/10.1016\/j.autrev.2025.103864","journal-title":"Autoimmun Reviews Elsevier B V"},{"key":"6258_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/J.JOT","volume":"32","author":"C Meurot","year":"2022","unstructured":"Meurot C, Jacques C, Martin C, Sudre L, Breton J, Rattenbach R et al (2022) Targeting the GLP-1\/GLP-1R axis to treat osteoarthritis: A new opportunity? J Orthop Translat 32:121. https:\/\/doi.org\/10.1016\/J.JOT.2022.02.001","journal-title":"J Orthop Translat"},{"issue":"3","key":"6258_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/phar.70005","volume":"45","author":"M Ryan","year":"2025","unstructured":"Ryan M, Megyeri S, Nuffer W, Trujillo JM (2025) The potential role of GLP-1 receptor agonists in osteoarthritis. Pharmacotherapy 45(3):177\u2013186. https:\/\/doi.org\/10.1002\/PHAR.70005","journal-title":"Pharmacotherapy"},{"issue":"3","key":"6258_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41584-025-01326-6","volume":"22","author":"RH Haberman","year":"2025","unstructured":"Haberman RH, Ogdie A, Merola JF, Scher JU, Eder L (2025) The obesity\u2013inflammation axis in psoriatic disease: mechanisms and therapeutic strategies. Nat Rev Rheumatol 22(3):3. https:\/\/doi.org\/10.1038\/s41584-025-01326-6","journal-title":"Nat Reviews Rheumatol 2025"},{"issue":"12","key":"6258_CR9","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1038\/NUTD.2012.26","volume":"2","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ (2012) The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2(12):e54. https:\/\/doi.org\/10.1038\/NUTD.2012.26","journal-title":"Nutr Diabetes"},{"issue":"3","key":"6258_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/acr.24121","volume":"73","author":"RS Thomsen","year":"2021","unstructured":"Thomsen RS, Nilsen TIL, Haugeberg G, Gulati AM, Kavanaugh A, Hoff M (2021) Adiposity and physical activity as risk factors for developing psoriatic arthritis: longitudinal data from a population-based study in Norway. Arthritis Care Res (Hoboken) 73(3):432\u2013441. https:\/\/doi.org\/10.1002\/ACR.24121","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"6258_CR11","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1136\/annrheumdis-2011-201273","volume":"71","author":"W Li","year":"2012","unstructured":"Li W, Han J, Qureshi AA (2012) Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 71(8):1267. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2011-201273","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"6258_CR12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1136\/annrheumdis-2012-201299","volume":"71","author":"TJ Love","year":"2012","unstructured":"Love TJ, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, Gelfand JM et al (2012) Obesity and the risk of psoriatic arthritis: A population-based study. Ann Rheum Dis 71(8):1273\u20131277. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201299","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"6258_CR13","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMOA2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S, Udd\u00e9n Hemmingsson J, Hjelmes\u00e6th J, Hoffmann Morville T et al (2024) Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med 391(17):1573\u20131583. https:\/\/doi.org\/10.1056\/NEJMOA2403664","journal-title":"N Engl J Med"},{"key":"6258_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/art.70170","author":"RH Haberman","year":"2026","unstructured":"Haberman RH, Rice AL, Chen K, Scher U, Thib S, Scher JU et al (2026) Glucagon-like peptide-1 receptor agonist therapy is associated with improvement in psoriatic arthritis\u2013related and metabolic outcomes: a retrospective analysis of two cohorts. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.70170","journal-title":"Arthritis Rheumatol"},{"key":"6258_CR15","doi-asserted-by":"publisher","unstructured":"Hammoud R, Drucker DJ (2022) 19:4 Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nature Rev Endocrinoly 2022;19(4):201\u201316. https:\/\/doi.org\/10.1038\/s41574-022-00783-3","DOI":"10.1038\/s41574-022-00783-3"},{"issue":"1","key":"6258_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C et al (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Therapy 2024 9(1):1. https:\/\/doi.org\/10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Therapy 2024"},{"key":"6258_CR17","doi-asserted-by":"publisher","unstructured":"Broks\u00f8 AD, Br\u00fcner M, Hartmann B, Josefsen K, Holst JJ, Kragstrup TW (2026) Detection of GLP-1 and DPP-4 in synovial fluid: implications for therapeutical strategies in arthritis. Lancet Rheumatol 0(0). https:\/\/doi.org\/10.1016\/S2665-9913","DOI":"10.1016\/S2665-9913"},{"issue":"17","key":"6258_CR18","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMe2409972","volume":"391","author":"DT Felson","year":"2024","unstructured":"Felson DT (2024) Glucagon-like peptide-1 receptor agonists and osteoarthritis. N Engl J Med 391(17):1643\u20131644. https:\/\/doi.org\/10.1056\/NEJME2409972","journal-title":"N Engl J Med"},{"key":"6258_CR19","doi-asserted-by":"publisher","unstructured":"Hogan AE, Davis C, Jenkins BJ, Jones N, O\u2019Shea D (2025) Repurposing metabolic drugs as anti-inflammatory agents. Trends Endocrinol Metabolism 0(0). https:\/\/doi.org\/10.1016\/j.tem.2025.07.003","DOI":"10.1016\/j.tem.2025.07.003"},{"key":"6258_CR20","doi-asserted-by":"publisher","first-page":"737079","DOI":"10.3389\/fmed.2021.737079","volume":"8","author":"L Novelli","year":"2021","unstructured":"Novelli L, Lubrano E, Venerito V, Perrotta FM, Marando F, Curradi G et al (2021) Extra-articular manifestations and comorbidities in psoriatic disease: a journey into the immunologic crosstalk. Front Med (Lausanne) 8:737079. https:\/\/doi.org\/10.3389\/FMED.2021.737079","journal-title":"Front Med (Lausanne)"},{"key":"6258_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.biochi.2023.04.008","volume":"212","author":"J Pestel","year":"2023","unstructured":"Pestel J, Blangero F, Watson J, Pirola L, Eljaafari A (2023) Adipokines in obesity and metabolic-related-diseases. Biochimie 212:48\u201359. https:\/\/doi.org\/10.1016\/J.BIOCHI.2023.04.008","journal-title":"Biochimie"},{"issue":"8","key":"6258_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1759720X18783894","volume":"10","author":"E Nikiphorou","year":"2018","unstructured":"Nikiphorou E, Fragoulis GE (2018) Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review. Ther Adv Musculoskelet Dis 10(8):157\u2013167. https:\/\/doi.org\/10.1177\/1759720X18783894","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"7371","key":"6258_CR23","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S0140-6736(","volume":"284","author":"D Ogston","year":"1964","unstructured":"Ogston D, Mcandrew GM, Fibrinolysis in obesity (1964) Lancet 284(7371):1205\u20131207. https:\/\/doi.org\/10.1016\/S0140-6736(64)91042-6","journal-title":"Lancet"},{"issue":"7640","key":"6258_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature21363","volume":"542","author":"GS Hotamisligil","year":"2017","unstructured":"Hotamisligil GS (2017) Inflammation, metaflammation and immunometabolic disorders. Nature 542(7640):177\u2013185. https:\/\/doi.org\/10.1038\/NATURE21363","journal-title":"Nature"},{"key":"6258_CR25","doi-asserted-by":"publisher","unstructured":"Schleh MW, Caslin HL, Garcia JN, Mashayekhi M, Srivastava G, Bradley AB et al (2023) Metaflammation in obesity and its therapeutic targeting. Sci Transl Med 15(723). https:\/\/doi.org\/10.1126\/SCITRANSLMED.ADF93820","DOI":"10.1126\/SCITRANSLMED.ADF93820"},{"key":"6258_CR26","doi-asserted-by":"publisher","first-page":"1759720X2412718","DOI":"10.1177\/1759720X241271886","volume":"16","author":"JC Williams","year":"2024","unstructured":"Williams JC, Hum RM, Rogers K, Maglio C, Alam U, Zhao SS (2024) Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy. Ther Adv Musculoskelet Dis 16:1759720X241271886. https:\/\/doi.org\/10.1177\/1759720X241271886","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"6258_CR27","doi-asserted-by":"publisher","unstructured":"Kumthekar A, Ogdie A (2020) 7:3 Obesity and psoriatic arthritis: a narrative review. Rheumatol Ther 2020;7(3):447\u201356. https:\/\/doi.org\/10.1007\/S40744-020-00215-6","DOI":"10.1007\/S40744-020-00215-6"},{"issue":"9","key":"6258_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/S41584-024-01143-3","volume":"20","author":"M Binvignat","year":"2024","unstructured":"Binvignat M, Sellam J, Berenbaum F, Felson DT (2024) The role of obesity and adipose tissue dysfunction in osteoarthritis pain. Nat Rev Rheumatol 20(9):565\u2013584. https:\/\/doi.org\/10.1038\/S41584-024-01143-3","journal-title":"Nat Rev Rheumatol"},{"key":"6258_CR29","doi-asserted-by":"publisher","unstructured":"Garcia MM, Corrales P, Huerta M, Czachorowski MJ, L\u00f3pez-Miranda V, Medina-G\u00f3mez G et al (2024) Adults with excess weight or obesity, but not with overweight, report greater pain intensities than individuals with normal weight: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 15. https:\/\/doi.org\/10.3389\/FENDO.2024.1340465","DOI":"10.3389\/FENDO.2024.1340465"},{"issue":"9","key":"6258_CR30","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/1756-185X.14147","volume":"24","author":"A Loganathan","year":"2021","unstructured":"Loganathan A, Kamalaraj N, El-Haddad C, Pile K (2021) Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis. Int J Rheum Dis 24(9):1112\u20131120. https:\/\/doi.org\/10.1111\/1756-185X.14147","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"6258_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS et al (2017) Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 76(3):377\u2013390. https:\/\/doi.org\/10.1016\/j.jaad.2016.07.064","journal-title":"J Am Acad Dermatol"},{"key":"6258_CR32","doi-asserted-by":"publisher","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ (2012) The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2(12). https:\/\/doi.org\/10.1038\/NUTD.2012.26","DOI":"10.1038\/NUTD.2012.26"},{"key":"6258_CR33","doi-asserted-by":"publisher","unstructured":"Russolillo A, Iervolino S, Peluso R, Lupoli R, Di minno A, Pappone N et al (2013) Obesity and psoriatic arthritis: From pathogenesis to clinical outcome and management. Rheumatology (United Kingdom). pp. 62\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kes242","DOI":"10.1093\/rheumatology\/kes242"},{"issue":"7","key":"6258_CR34","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/archdermatol.2010.141","volume":"146","author":"R Soltani-Arabshahi","year":"2010","unstructured":"Soltani-Arabshahi R, Wong B, Feng BJ, Goldgar DE, Callis Duffin K, Krueger GG (2010) Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol 146(7):721\u2013726. https:\/\/doi.org\/10.1001\/ARCHDERMATOL.2010.141","journal-title":"Arch Dermatol"},{"issue":"12","key":"6258_CR35","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.soard.2024.07.011","volume":"20","author":"A Hosseininasab","year":"2024","unstructured":"Hosseininasab A, Mosavari H, Rostami A, Bahardoust M, Izadi A, Jaliliyan A et al (2024) The long-term impact of bariatric surgery on psoriasis symptoms and severity: a prospective observational study. Surg Obes Relat Dis 20(12):1208\u20131213. https:\/\/doi.org\/10.1016\/J.SOARD.2024.07.011","journal-title":"Surg Obes Relat Dis"},{"key":"6258_CR36","doi-asserted-by":"publisher","unstructured":"Dakanalis A, Mentzelou M, Papadopoulou SK, Papandreou D, Spanoudaki M, Vasios GK et al (2023) The association of emotional eating with overweight\/obesity, depression, anxiety\/stress, and dietary patterns: a review of the current clinical evidence. Nutrients 15(5). https:\/\/doi.org\/10.3390\/NU15051173","DOI":"10.3390\/NU15051173"},{"issue":"4","key":"6258_CR37","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.joca.2021.12.003","volume":"30","author":"P Dainese","year":"2022","unstructured":"Dainese P, Wyngaert KV, De Mits S, Wittoek R, Van Ginckel A, Calders P (2022) Association between knee inflammation and knee pain in patients with knee osteoarthritis: a systematic review. Osteoarthritis Cartilage 30(4):516\u2013534. https:\/\/doi.org\/10.1016\/j.joca.2021.12.003","journal-title":"Osteoarthritis Cartilage"},{"issue":"10","key":"6258_CR38","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/17581869.2025.2536998","volume":"15","author":"S Bade","year":"2025","unstructured":"Bade S, Hurdle MFB, Bade S, Encalada S, Kanahan-Osman S, Gupta S (2025) GLP-1 agonists: a game changer in pain treatment and addiction. Pain Manag 15(10):753\u2013765. https:\/\/doi.org\/10.1080\/17581869.2025.2536998","journal-title":"Pain Manag"},{"issue":"9","key":"6258_CR39","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/acr.25101","volume":"75","author":"B Conley","year":"2023","unstructured":"Conley B, Bunzli S, Bullen J, O\u2019Brien P, Persaud J, Gunatillake T et al (2023) Core recommendations for osteoarthritis care: a systematic review of clinical practice guidelines. Arthritis Care Res (Hoboken) 75(9):1897\u20131907. https:\/\/doi.org\/10.1002\/ACR.25101","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"6258_CR40","doi-asserted-by":"publisher","first-page":"548","DOI":"10.31138\/mjr.050225.hre","volume":"36","author":"M Sakkou","year":"2025","unstructured":"Sakkou M, Mourikis A, Fanourgiakis I, Vossos A, Tektonidou M, Fragoulis GE et al (2025) Differential neutrophil and eosinophil infiltrations in the sub-lining compartment of rheumatoid versus osteoarthritic synovium. Mediterr J Rheumatol 36(4):548\u2013556 https:\/\/doi.org\/10.31138\/mjr.050225.hre","journal-title":"Mediterr J Rheumatol"},{"issue":"7","key":"6258_CR41","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.joca.2017.01","volume":"25","author":"C Manferdini","year":"2017","unstructured":"Manferdini C, Paolella F, Gabusi E, Gambari L, Piacentini A, Filardo G et al (2017) Adipose stromal cells mediated switching of the pro-inflammatory profile of M1-like macrophages is facilitated by PGE2: in vitro evaluation. Osteoarthritis Cartilage 25(7):1161\u20131171. https:\/\/doi.org\/10.1016\/j.joca.2017.01","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"6258_CR42","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/S41598-022-05323-7","volume":"12","author":"C Meurot","year":"2022","unstructured":"Meurot C, Martin C, Sudre L, Breton J, Bougault C, Rattenbach R et al (2022) Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep 12(1):1567. https:\/\/doi.org\/10.1038\/S41598-022-05323-7 PubMed PMID: 35091584","journal-title":"Sci Rep"},{"key":"6258_CR43","doi-asserted-by":"publisher","unstructured":"Wan S, Sun H (2019) Glucagon-like peptide-1 modulates RAW264.7 macrophage polarization by interfering with the JNK\/STAT3 signaling pathway. Exp Ther Med 17(5). https:\/\/doi.org\/10.3892\/ETM.2019.7347","DOI":"10.3892\/ETM.2019.7347"},{"issue":"3","key":"6258_CR44","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1124\/jpet.102.037481","volume":"302","author":"T Perry","year":"2002","unstructured":"Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH (2002) Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302(3):881\u2013888. https:\/\/doi.org\/10.1124\/jpet.102.037481","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"6258_CR45","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/bph.12895","volume":"172","author":"H Fan","year":"2015","unstructured":"Fan H, Gong N, Li TF, Ma AN, Wu XY, Wang MW et al (2015) The non-peptide GLP-1 receptor agonist WB4-24 blocks inflammatory nociception by stimulating \u03b2-endorphin release from spinal microglia. Br J Pharmacol 172(1):64\u201379. https:\/\/doi.org\/10.1111\/BPH.12895","journal-title":"Br J Pharmacol"},{"issue":"1","key":"6258_CR46","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/S10194-024-01821-3","volume":"25","author":"W Halloum","year":"2024","unstructured":"Halloum W, Dughem Y, Al, Beier D, Pellesi L (2024) Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review. J Headache Pain 25(1):112. https:\/\/doi.org\/10.1186\/S10194-024-01821-3","journal-title":"J Headache Pain"},{"issue":"4","key":"6258_CR47","first-page":"2081","volume":"11","author":"C Tong","year":"2019","unstructured":"Tong C, Liang H, Liu X, Yuan B, Xue B, Tong Z et al (2019) The protective effects of exenatide against AGEs-induced articular matrix degradation in human primary chondrocytes. Am J Transl Res 11(4):2081","journal-title":"Am J Transl Res"},{"issue":"3","key":"6258_CR48","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.cmet.2026.01.008","volume":"38","author":"H Qin","year":"2026","unstructured":"Qin H, Yu J, Yu H, Zhou C, Yuan D, Wang Z et al (2026) Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism. Cell Metab 38(3):582\u2013597e6. https:\/\/doi.org\/10.1016\/j.cmet.2026.01.008","journal-title":"Cell Metab"},{"issue":"11","key":"6258_CR49","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/acr.23608","volume":"70","author":"SP Messier","year":"2018","unstructured":"Messier SP, Resnik AE, Beavers DP, Mihalko SL, Miller GD, Nicklas BJ et al (2018) Intentional weight loss in overweight and obese patients with knee osteoarthritis: is more better? Arthritis Care Res (Hoboken) 70(11):1569\u20131575. https:\/\/doi.org\/10.1002\/ACR.23608","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"6258_CR50","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/S00125-013-3145-0","volume":"57","author":"AE Hogan","year":"2014","unstructured":"Hogan AE, Gaoatswe G, Lynch L, Corrigan MA, Woods C, O\u2019Connell J et al (2014) Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia 57(4):781\u2013784. https:\/\/doi.org\/10.1007\/S00125-013-3145-0","journal-title":"Diabetologia"},{"issue":"1","key":"6258_CR51","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1210\/jc.2011-1508","volume":"97","author":"A Chaudhuri","year":"2012","unstructured":"Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, Dhindsa S et al (2012) Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab 97(1):198\u2013207. https:\/\/doi.org\/10.1210\/JC.2011-1508","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"6258_CR52","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1111\/dom.14399","volume":"23","author":"JJH Bray","year":"2021","unstructured":"Bray JJH, Foster-Davies H, Salem A, Hoole AL, Obaid DR, Halcox JPJ et al (2021) Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab 23(8):1806\u20131822. https:\/\/doi.org\/10.1111\/DOM.14399","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"6258_CR53","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/AJCN\/NQAA328","volume":"113","author":"H Gudbergsen","year":"2021","unstructured":"Gudbergsen H, Overgaard A, Henriksen M, W\u00e6hrens EE, Bliddal H, Christensen R et al (2021) Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. Am J Clin Nutr 113(2):314\u2013323. https:\/\/doi.org\/10.1093\/AJCN\/NQAA328 PubMed PMID: 33471039","journal-title":"Am J Clin Nutr"},{"issue":"9","key":"6258_CR54","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/ard-2023-223845","volume":"82","author":"H Zhu","year":"2023","unstructured":"Zhu H, Zhou L, Wang Q, Cai Q, Yang F, Jin H et al (2023) Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: Findings from the Shanghai Osteoarthritis Cohort. Ann Rheum Dis 82(9):1218\u20131226. https:\/\/doi.org\/10.1136\/ard-2023-223845","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"6258_CR55","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.arth.2024.06.008","volume":"39","author":"MS Lavu","year":"2024","unstructured":"Lavu MS, Porto JR, Hecht CJ, Kaelber DC, Sculco PK, Heckmann ND et al (2024) The five-year incidence of progression to osteoarthritis and total joint arthroplasty in patients prescribed glucagon-like peptide 1 receptor agonists. J Arthroplasty 39(10):2433\u20132439.e1. https:\/\/doi.org\/10.1016\/J.ARTH.2024.06.008","journal-title":"J Arthroplasty"},{"key":"6258_CR56","doi-asserted-by":"publisher","unstructured":"Porto JR, Lavu MS, Hecht CJ, Kaelber DC, Sculco PK, Heckmann ND et al (2025) The impact of contemporary glucagon-like peptide-1 receptor agonists on the onset, severity, and conversion to arthroplasty in hip and knee osteoarthritis. Orthop J Sports Med 13(1). https:\/\/doi.org\/10.1177\/23259671241297157","DOI":"10.1177\/23259671241297157"},{"issue":"3","key":"6258_CR57","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000519008","volume":"27","author":"K Kikkawa","year":"2021","unstructured":"Kikkawa K, Hoshi H, Isoda A, Okada K, Okada J, Watanabe T et al (2021) Long-acting glucagon-like peptide-1 receptor agonist-induced rheumatoid arthritis in a patient with type 2 diabetes mellitus. Dubai Diabetes Endocrinol J 27(3):114\u2013117. https:\/\/doi.org\/10.1159\/000519008","journal-title":"Dubai Diabetes Endocrinol J"},{"issue":"4","key":"6258_CR58","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/S00592-013-0525-3","volume":"51","author":"ML Ambrosio","year":"2014","unstructured":"Ambrosio ML, Monami M, Sati L, Marchionni N, Di Bari M, Mannucci E (2014) GLP-1 receptor agonist-induced polyarthritis: a case report. Acta Diabetol 51(4):673\u2013674. https:\/\/doi.org\/10.1007\/S00592-013-0525-3","journal-title":"Acta Diabetol"},{"issue":"8","key":"6258_CR59","doi-asserted-by":"publisher","first-page":"e0237598","DOI":"10.1371\/journal.pone.0237598","volume":"15","author":"T Blake","year":"2020","unstructured":"Blake T, Gullick NJ, Hutchinson CE, Barber TM (2020) Psoriatic disease and body composition: a systematic review and narrative synthesis. PLoS ONE 15(8):e0237598. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0237598","journal-title":"PLoS ONE"},{"issue":"7","key":"6258_CR60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/S11926-018-0753-1\/TABLES\/4","volume":"20","author":"F Prignano","year":"2018","unstructured":"Prignano F, Rogai V, Cavallucci E, Bitossi A, Hammen V, Cantini F (2018) Epidemiology of psoriasis and psoriatic arthritis in italy\u2014a systematic review. Curr Rheumatol Rep 20(7):43. https:\/\/doi.org\/10.1007\/S11926-018-0753-1\/TABLES\/4","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"6258_CR61","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/S12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A (2018) The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol 55(3):379. https:\/\/doi.org\/10.1007\/S12016-018-8702-3","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"6258_CR62","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/ard-2024-225534","volume":"83","author":"A Kerschbaumer","year":"2024","unstructured":"Kerschbaumer A, Smolen JS, Ferreira RJO, Bertheussen H, Baraliakos X, Aletaha D et al (2024) Efficacy and safety of pharmacological treatment of psoriatic arthritis: A systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 83(6):760\u2013774. https:\/\/doi.org\/10.1136\/ard-2024-225534","journal-title":"Ann Rheum Dis"},{"key":"6258_CR63","doi-asserted-by":"publisher","first-page":"122991","DOI":"10.1016\/j.lfs.2024.122991","volume":"355","author":"D Sugumaran","year":"2024","unstructured":"Sugumaran D, Yong ACH, Stanslas J (2024) Advances in psoriasis research: From pathogenesis to therapeutics. Life Sci 355:122991. https:\/\/doi.org\/10.1016\/J.LFS.2024.122991","journal-title":"Life Sci"},{"issue":"4","key":"6258_CR64","doi-asserted-by":"publisher","first-page":"418","DOI":"10.31138\/mjr.301223.dpa","volume":"34","author":"GE Fragoulis","year":"2023","unstructured":"Fragoulis GE, Papagoras C, Gazi S, Mole E, Krikelis M, Voulgari PV et al (2023) Disease profile and achievement of therapeutic goals in a modern, nationwide cohort of 923 patients with psoriatic arthritis. Mediterr J Rheumatol 34(4):418\u2013426. https:\/\/doi.org\/10.31138\/MJR.301223.DPA","journal-title":"Mediterr J Rheumatol"},{"key":"6258_CR65","doi-asserted-by":"publisher","unstructured":"Klingberg E, Bilberg A, Bj\u00f6rkman S, Hedberg M, Jacobsson L, Forsblad-D\u2019Elia H et al (2019) Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther 21(1). https:\/\/doi.org\/10.1186\/S13075-019-1810-5","DOI":"10.1186\/S13075-019-1810-5"},{"key":"6258_CR66","doi-asserted-by":"publisher","unstructured":"Leung YY, Eder L, Orbai AM, Coates LC, De Wit M, Smolen JS et al (2023) Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study. RMD Open 9(3). https:\/\/doi.org\/10.1136\/rmdopen-2023-003157","DOI":"10.1136\/rmdopen-2023-003157"},{"issue":"9","key":"6258_CR67","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1093\/rheumatology\/keae263","volume":"63","author":"KD Vassilakis","year":"2024","unstructured":"Vassilakis KD, Papagoras C, Fytanidis N, Gazi S, Mole E, Krikelis M et al (2024) Identification and characteristics of patients with potential difficult-to-treat psoriatic arthritis: exploratory analyses of the Greek PsA registry. Rheumatology (Oxford) 63(9):2427\u20132432. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEAE263","journal-title":"Rheumatology (Oxford)"},{"key":"6258_CR68","doi-asserted-by":"publisher","unstructured":"Lob\u00e3o B, Louren\u00e7o D, Giga A, Mendes-Bastos P (2024) From PsO to PsA: the role of TRM and Tregs in psoriatic disease, a systematic review of the literature. Front Med (Lausanne) 11. https:\/\/doi.org\/10.3389\/FMED.2024.1346757","DOI":"10.3389\/FMED.2024.1346757"},{"key":"6258_CR69","doi-asserted-by":"publisher","unstructured":"Liu XQ, Zhou PL, Yin XY, Wang AX, Wang DH, Yang Y et al (2023) Circulating inflammatory cytokines and psoriasis risk: A systematic review and meta-analysis. PLoS ONE 18(10). https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0293327","DOI":"10.1371\/JOURNAL.PONE.0293327"},{"issue":"1","key":"6258_CR70","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.18632\/oncotarget.22260","volume":"9","author":"F Bai","year":"2017","unstructured":"Bai F, Zheng W, Dong Y, Wang J, Garstka MA, Li R et al (2017) Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis. Oncotarget 9(1):1266\u20131278. https:\/\/doi.org\/10.18632\/ONCOTARGET.22260","journal-title":"Oncotarget"},{"key":"6258_CR71","doi-asserted-by":"publisher","unstructured":"Klingberg E, Bj\u00f6rkman S, Eliasson B, Larsson I, Bilberg A (2020) Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up. Arthritis Res Ther 22(1). https:\/\/doi.org\/10.1186\/S13075-020-02350-5","DOI":"10.1186\/S13075-020-02350-5"},{"issue":"6","key":"6258_CR72","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","volume":"73","author":"MND Di Minno","year":"2014","unstructured":"Di Minno MND, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R (2014) Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers. Ann Rheum Dis 73(6):1157\u20131162. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202812","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6258_CR73","doi-asserted-by":"publisher","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, Casteele N, Vande, Zarrinpar A, Prokop LJ et al (2018) Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS ONE 13(5):e0195123. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0195123","journal-title":"PLoS ONE"},{"key":"6258_CR74","doi-asserted-by":"publisher","unstructured":"Patsalos O, Dalton B, Leppanen J, Ibrahim MAA, Himmerich H (2020) Impact of TNF-\u03b1 inhibitors on body weight and BMI: a systematic review and meta-analysis. Front Pharmacol 11. https:\/\/doi.org\/10.3389\/FPHAR.2020.00481","DOI":"10.3389\/FPHAR.2020.00481"},{"issue":"6","key":"6258_CR75","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjd.20971","volume":"186","author":"M Augustin","year":"2022","unstructured":"Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S et al (2022) Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol 186(6):942\u2013954. https:\/\/doi.org\/10.1111\/BJD.20971","journal-title":"Br J Dermatol"},{"issue":"8","key":"6258_CR76","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3899\/jrheum.210912","volume":"49","author":"T Nguyen","year":"2022","unstructured":"Nguyen T, Churchill M, Levin R, Valenzuela G, Merola JF, Ogdie A et al (2022) Secukinumab in United States Biologic-Na\u00efve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study. J Rheumatol 49(8):894\u2013902. https:\/\/doi.org\/10.3899\/JRHEUM.210912","journal-title":"J Rheumatol"},{"issue":"1","key":"6258_CR77","doi-asserted-by":"publisher","first-page":"7051","DOI":"10.1038\/S41598-026-37835-X","volume":"16","author":"S Gentileschi","year":"2026","unstructured":"Gentileschi S, Terribili R, Gaggiano C, Fiorentini E, Cometi L, Cigolini C et al (2026) Ixekizumab for the treatment of psoriatic arthritis: an Italian multicentric retrospective observational study. Sci Rep 16(1):7051. https:\/\/doi.org\/10.1038\/S41598-026-37835-X","journal-title":"Sci Rep"},{"issue":"3","key":"6258_CR78","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1080\/09546634.2020.1853023","volume":"33","author":"M Shahriari","year":"2022","unstructured":"Shahriari M, Harrison RW, Burge R, Lin CY, Malatestinic WN, Goldblum OM et al (2022) Disease response and patient-reported outcomes among initiators of ixekizumab. J Dermatolog Treat 33(3):1538\u20131546. https:\/\/doi.org\/10.1080\/09546634.2020.1853023","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"6258_CR79","doi-asserted-by":"publisher","first-page":"E42","DOI":"10.1136\/annrheumdis-2020-217251","volume":"81","author":"I Pantano","year":"2022","unstructured":"Pantano I, Iacono D, Favalli EG, Scalise G, Costa L, Caso F et al (2022) Secukinumab efficacy in patients with PsA is not dependent on patients\u2019 body mass index. Ann Rheum Dis 81(3):E42. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217251","journal-title":"Ann Rheum Dis"},{"key":"6258_CR80","doi-asserted-by":"publisher","unstructured":"Gialouri CG, Pappa M, Evangelatos G, Nikiphorou E, Fragoulis GE (2023) Effect of body mass index on treatment response of biologic\/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review. Autoimmun Rev 22(7). https:\/\/doi.org\/10.1016\/j.autrev.2023.103357 PubMed PMID: 37150489","DOI":"10.1016\/j.autrev.2023.103357"},{"issue":"5","key":"6258_CR81","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.immuni.2015.04.016","volume":"42","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Li Q, Rao E, Sun Y, Grossmann ME, Morris RJ et al (2015) Epidermal fatty acid binding protein promotes high-fat diet-induced skin inflammation. Immunity 42(5):953 https:\/\/doi.org\/10.1016\/j.immuni.2015.04.016","journal-title":"Immunity"},{"issue":"8","key":"6258_CR82","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.immuni.2023.06.021","volume":"56","author":"P Sivasami","year":"2023","unstructured":"Sivasami P, Elkins C, Diaz-Saldana PP, Goss K, Peng A, Hamersky M et al (2023) Obesity-induced dysregulation of skin-resident PPAR\u03b3\u2009+\u2009Treg cells promotes IL-17A-mediated psoriatic inflammation. Immunity 56(8):1844\u20131861e6. https:\/\/doi.org\/10.1016\/j.immuni.2023.06.021 PubMed PMID: 37478855","journal-title":"Immunity"},{"issue":"1","key":"6258_CR83","doi-asserted-by":"publisher","first-page":"14076","DOI":"10.1038\/S41598-017-14292-1","volume":"7","author":"S Nakamizo","year":"2017","unstructured":"Nakamizo S, Honda T, Adachi A, Nagatake T, Kunisawa J, Kitoh A et al (2017) High fat diet exacerbates murine psoriatic dermatitis by increasing the number of IL-17-producing \u03b3\u03b4 T cells. Sci Rep 7(1):14076. https:\/\/doi.org\/10.1038\/S41598-017-14292-1","journal-title":"Sci Rep"},{"issue":"5","key":"6258_CR84","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cell","volume":"177","author":"DA Mogilenko","year":"2019","unstructured":"Mogilenko DA, Haas JT, L\u2019homme L, Fleury S, Quemener S, Levavasseur M et al (2019) Metabolic and Innate Immune Cues Merge into a Specific Inflammatory Response via the UPR. Cell 177(5):1201\u20131216e19. https:\/\/doi.org\/10.1016\/j.cell","journal-title":"Cell"},{"issue":"10","key":"6258_CR85","doi-asserted-by":"publisher","first-page":"e3491","DOI":"10.7759\/cureus.3491","volume":"10","author":"HA Alotaibi","year":"2018","unstructured":"Alotaibi HA (2018) Effects of weight loss on psoriasis: a review of clinical trials. Cureus 10(10):e3491 https:\/\/doi.org\/10.7759\/cureus.3491","journal-title":"Cureus"},{"issue":"1","key":"6258_CR86","doi-asserted-by":"publisher","first-page":"501809","DOI":"10.1016\/j.reuma.2024.501809","volume":"21","author":"J Nicolau","year":"2025","unstructured":"Nicolau J, Nadal A, Ros I, Masmiquel L (2025) Effects of liraglutide among patients with psoriatic arthritis and obesity. Reumatol Clin 21(1):501809. https:\/\/doi.org\/10.1016\/J.REUMAE.2025.501809","journal-title":"Reumatol Clin"},{"issue":"3","key":"6258_CR87","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","volume":"33","author":"L Lin","year":"2022","unstructured":"Lin L, Xu X, Yu Y, Ye H, He X, Chen S et al (2022) Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J Dermatolog Treat 33(3):1428\u20131434. https:\/\/doi.org\/10.1080\/09546634.2020.1826392 PubMed PMID: 32962477","journal-title":"J Dermatolog Treat"},{"issue":"0","key":"6258_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ART.70134","volume":"0","author":"JF Merola","year":"2026","unstructured":"Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D et al (2026) Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: results from a randomized clinical trial. Arthritis Rheumatol 0(0):1\u201313. https:\/\/doi.org\/10.1002\/ART.70134","journal-title":"Arthritis Rheumatol"},{"key":"6258_CR89","doi-asserted-by":"publisher","unstructured":"Lebwohl M, Blauvelt A, Kartman CE, Leatherwood C, Gordon KB, Sattar N et al (2026 Ixekizumab with or without tirzepatide in adults with psoriasis and overweight or obesity. JAMA Dermatol 15. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2026.1753","DOI":"10.1001\/JAMADERMATOL.2026.1753"},{"issue":"3","key":"6258_CR90","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ard.2025.08.013","volume":"85","author":"N Kyriazi","year":"2026","unstructured":"Kyriazi N, Vassilakis KD, Bakiri A, Iliopoulos A, Fragoulis GE (2026) Antiobesity medications in rheumatology. Quo vadis? Ann Rheum Dis 85(3):412\u2013416. https:\/\/doi.org\/10.1016\/J.ARD.2025.08.013","journal-title":"Quo vadis? Ann Rheum Dis"},{"key":"6258_CR91","doi-asserted-by":"publisher","unstructured":"Cani PD, Van Hul M (2023) Gut microbiota in overweight and obesity: crosstalk with adipose tissue. Nat Rev Gastroenterol Hepatol 21(3):164\u201383. https:\/\/doi.org\/10.1038\/s41575-023-00867-z","DOI":"10.1038\/s41575-023-00867-z"},{"issue":"1","key":"6258_CR92","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/art.38892","volume":"67","author":"JU Scher","year":"2015","unstructured":"Scher JU, Ubeda C, Artacho A, Attur M, Isaac S, Reddy SM et al (2015) Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol 67(1):128\u2013139. https:\/\/doi.org\/10.1002\/ART.38892","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"6258_CR93","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/bjd.18227","volume":"182","author":"A Green","year":"2020","unstructured":"Green A, Shaddick G, Charlton R, Snowball J, Nightingale A, Smith C et al (2020) Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. Br J Dermatol 182(3):714\u2013720. https:\/\/doi.org\/10.1111\/BJD.18227","journal-title":"Br J Dermatol"},{"issue":"6","key":"6258_CR94","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMOA2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, Wu Q, Du Y, Gurbuz S et al (2023) Triple\u2013hormone-receptor agonist retatrutide for obesity \u2014 a phase 2 Trial. N Engl J Med 389(6):514\u2013526. https:\/\/doi.org\/10.1056\/NEJMOA2301972","journal-title":"N Engl J Med"},{"issue":"2","key":"6258_CR95","doi-asserted-by":"publisher","first-page":"rkad053","DOI":"10.1093\/rap\/rkad053","volume":"7","author":"P Mielnik","year":"2023","unstructured":"Mielnik P, Sexton J, Fagerli KM, Bakland G, Hu Y, Kristianslund EK et al (2023) Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD). Rheumatol Adv Pract 7(2):rkad053. https:\/\/doi.org\/10.1093\/RAP\/RKAD053","journal-title":"Rheumatol Adv Pract"},{"key":"6258_CR96","doi-asserted-by":"publisher","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L (2022) Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne) 13. https:\/\/doi.org\/10.3389\/FENDO.2022.1043789","DOI":"10.3389\/FENDO.2022.1043789"},{"issue":"4","key":"6258_CR97","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/THY.2023.0530","volume":"34","author":"AE De Espinosa","year":"2024","unstructured":"De Espinosa AE, Brito JP, McCoy RG, Shao H, Singh Ospina N (2024) Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review. Thyroid 34(4):403\u2013418. https:\/\/doi.org\/10.1089\/THY.2023.0530","journal-title":"Thyroid"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06258-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06258-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06258-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T03:37:58Z","timestamp":1786937878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06258-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":97,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["6258"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06258-2","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AA and CP declare no conflict of interest. DD has received speaking fees and honoraria for participation in advisory boards from UCB, Pfizer, MSD, Janssen, Abbvie, Lilly, Boehringer, Astra Zeneca and GSK. GEF has received speaker fees and honoraria for participation in advisory boards from UCB, Pfizer, Lilly, Novartis, Abbvie, Boehringer, Jannsen and Faran.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors used AI-assisted tools (Claude) to support language editing and structural organization. All AI-generated or AI-assisted content was carefully reviewed, verified and revised by the authors, who take full responsibility for the accuracy and integrity of the final manuscript. No AI tool was used as an author or to generate original scientific conclusions.","order":2,"name":"Ethics","label":"AI assistance","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"219"}}